Abstract 3607
Background
We aimed to establish a prognostic model based on magnetic resonance imaging using deep learning to predict disease-free survival in patients with non-metastatic nasopharyngeal carcinoma.
Methods
In this retrospective, cohort study, we included 1636 patients who were diagnosed with non-metastatic nasopharyngeal carcinoma and underwent radical treatment at the Sun Yat-sen University Cancer Center. Patients from October 2010 to March 2015 were randomly divided into training cohort (n = 878) and validation cohort (n = 376); 382 patients from April 2015 to September 2015 were separated as test cohort. 3D DenseNet models learned deep representations of pre-treatment MRI and risk scores were extracted to predict PFS in the training cohort. We evaluated the accuracy of the prognostic model in validation and test cohorts. The primary endpoint was DFS, and the secondary endpoint was distant metastasis-free survival (DMFS).
Results
A series of risk scores for each patient were extracted from 3D DenseNet models, and an optimal cut-off value of risk scores was generated to classify patients into low-risk and high-risk group in the training cohort. Patients with low-risk scores had better DFS (hazard ratio [HR] 0.62, 95% CI 0.55 -0.70; p < 0.0001) and DMFS (HR 0.62, 95% CI 0.48 -0.81; p < 0.0003) than patients with low-risk scores. And we validated the prognostic accuracy of risk scores in the validation and test cohorts. In addition, patients who received concurrent chemotherapy had a poorer DFS (hazard ratio [HR] 7.79, 95% CI 1.08 -56.00; p < 0.041) compared with those who did not receive concurrent chemotherapy in low-risk group, meanwhile, patients with or without concurrent chemotherapy had similar outcomes in the high-risk group (HR 2.39, 95% CI 0.59 -9.62; p = 0.22). We also developed a nomogram based on risk scores and several clinical factors that predicted an individual’s risk of DFS.
Conclusions
MRI-based 3D DenseNet models are effective tools to learn deep representations and extract risk scores of DFS. Risk scores can be reliable prognostic factors to select which patients benefit from concurrent chemotherapy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
The National Natural Science Foundation of China.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1291 - PD-L1 expression in uncommon EGFR-mutant non-small cell lung cancer and its response to immunotherapy
Presenter: Yun Fan
Session: Poster Display session 3
Resources:
Abstract
2171 - CCND1 Amplification Contributes to Immunosuppression in Head and Neck Squamous Cell Carcinoma and the Association with a Poor Response to Immune Checkpoint Inhibitors
Presenter: Chloe Huang
Session: Poster Display session 3
Resources:
Abstract
2624 - Efficacy of PD-1/PD-L1 inhibitors in the treatment of non-small cell lung cancer patients with sensitive genes mutation
Presenter: Hui-Juan Cui
Session: Poster Display session 3
Resources:
Abstract
3494 - Neutrophil to Lymphocyte Ratio (NLR) kinetics as predictors of outcomes in metastatic renal cell carcinoma (mRCC) and non-small cell lung cancer (NSCLC) patients treated with nivolumab (N).
Presenter: Audrey Simonaggio
Session: Poster Display session 3
Resources:
Abstract
3964 - Predictive markers of checkpoint inhibitor activity in adult metastatic solid tumours
Presenter: Alexandra Pender
Session: Poster Display session 3
Resources:
Abstract
3041 - Blood-based TMB (bTMB) correlates with tissue-based TMB (tTMB) in a multi-cancer Phase I IO Cohort
Presenter: Daniel Araujo
Session: Poster Display session 3
Resources:
Abstract
3910 - Analysis of Molecular Profile Complexities for Immunotherapy Decision Support
Presenter: Robert Dóczi
Session: Poster Display session 3
Resources:
Abstract
4836 - The Role of Tumor Neoantigens in the Differential Response to Immunotherapy (IO) in EGFR and BRAF Mutated Lung Cancers - Quantity or Quality?
Presenter: Katrina Case
Session: Poster Display session 3
Resources:
Abstract
1929 - Impact of previous corticosteroid (CS) exposure on efficacy of Programmed Cell Death-(Ligand) 1 blockade in patients with advanced Non-Small-Cell Lung Cancer (NSCLC): a single Center retrospective analysis
Presenter: Fabrizio Nelli
Session: Poster Display session 3
Resources:
Abstract
2601 - Comparison 18F-FDG-PET/CT criteria for prediction of therapy response and clinical outcome in patients with metastatic melanoma treated with Ipilimumab and PD-1 inhibitors
Presenter: Sabrina Vari
Session: Poster Display session 3
Resources:
Abstract